[Therapy of chronic viral hepatitis type B in children after previous ineffective interferon-alpha treatment]

[Therapy of chronic viral hepatitis type B in children after previous ineffective interferon-alpha treatment] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[Therapy of chronic viral hepatitis type B in children after previous ineffective interferon-alpha treatment] Abstract Text:

THE AIM of this study was to estimate the efficacy of nucleoside analogue (lamivudine) in the therapy of chronic viral hepatitis type B in children, after previous, ineffective treatment with interferon-alpha. PATIENTS AND METHODS: we analyzed 53 children with chronic viral hepatitis type B, who had not responded to Interferon-alpha treatment conducted 1-7,5 years before this study (mean 4,0 +/- 7,5; median 4 years). Inclusive criteria to re-therapy with lamivudine were as follows: increased serum alanine aminotransferase activity, detected at least three times during 6 months before treatment, HBsAg and HBeAg present in the blood, viral HBV DNA detected for at least 6 months before the beginning of lamivudine therapy (above 200 genome copies per mL) and inflammation activity observed in liver biopsy specimen (biopsy performed within previous 24 months). Evaluation of side-effects of lamivudine therapy was based on anamnesis (subjective data) and laboratory tests performed regularly in the time of clinical visits during and after the end of the treatment. RESULTS: all the children concluded the treatment. Before lamivudine therapy, serum alanine aminotransferase activity ranged between 20-590 IU/L. In 28,4% of children it was less than 100 IU/L. In almost all the children moderate staging and grading were observed in liver biopsy specimens. HBV DNA in serum ranged between 200-200000 copies/mL: in 31 children (58,4%) HBV DNA exceeded 200000 copies/mL, in 5 (28,3%) was between 10000 and 200000 copies/mL, and in 7 (13,2% ) was below 10000 copies/mL. Applied treatment resulted in alanine aminotransferase activity normalization in 79,2% of children, mostly after 2-11 months (mean 3,9 +/- 2,7; median 3,8 months). HBeAg/HBeAb seroconversion was achieved in 28,3% of children, usually at the end of lamivudine therapy (approximately after 12 months). Sustained viral response was observed in 24,5% of treated children. There were no undesirable effects of therapy noted. Serum alanine aminotransferase activity increased slightly and temporarily in 4 children between 3rd and 12th month of therapy. In 2 of these children YMDD mutation was detected. CONCLUSIONS: lamivudine is effective, safe and well tolerated in treatment of chronic viral hepatitis type B, following unsuccessful interferon-alpha therapy. Serum alanine aminotransferase activity normalized in most of the patients. HBeAg/HBeAb seroconversion as well as positive viral response is mostly connected with low level of HBV DNA before therapy.

[Therapy of chronic viral hepatitis type B in children after previous ineffective interferon-alpha treatment] Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE: 2007 Oct-Dec

[Therapy of chronic viral hepatitis type B in children after previous ineffective interferon-alpha treatment] Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Medycyna wieku rozwojowego

VOLUME: 11

Page Numbers: 373-9

Journal Abbreviation:

ISSN: 1428-345X

DAY: 7

MONTH: 07

YEAR: 2008

[Therapy of chronic viral hepatitis type B in children after previous ineffective interferon-alpha treatment] Information

Number of References:

LANGUAGE: pol

NlmUniqueID: 100928610

[Therapy of chronic viral hepatitis type B in children after previous ineffective interferon-alpha treatment] Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: [Therapy of chronic viral hepatitis type B in children after previous ineffective interferon-alpha treatment] Information

Substance Name:

Registry Number:

Grant and Affiliation Information for [Therapy of chronic viral hepatitis type B in children after previous ineffective interferon-alpha treatment]

AFFILIATION: Katedra i Klinika Pediatrii, Gastroenterologii i Onkologii Dzieciecej Akademii Medycznej w Gda?sku. alib@amg.gda.pl

Country: Poland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Med Wieku Rozwoj

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Therapy of chronic viral hepatitis type B in children after previous ineffective interferon-alpha treatment Related Publications

• Acute acalculous cholecystitis of viral etiology--a rare condition in children?
• Serum gastrin concentration and changes in G and D cell densities in gastric antrum in children with chronic gastritis.
• [Case of Sprengel's deformity associated with Klippel-Feil syndrome]
• [Clinical importance of tryptophan metabolism disorders]
• [Intestinal absorption of iron in children with gastric and duodenal ulcer]
• [Medium-chain fats in dietetic treatment of some disorders of the digestive tract]
• [Medium-chain triglyceride (MCT) therapy in a case of generalized lymphangiectasia with intestinal loss of proteins]
• [New method of surgical treatment of fractures of the condylar process of the mandible]
• [Psychomotor development of children and infants suffering from toxic diarrhea]
• [Reactive oxygen species and antioxidative barrier in asthma.]
• [Therapy of chronic viral hepatitis type B in children after previous ineffective interferon-alpha treatment]
• [Xanthurenic acid excretion in acute leukemia in children]